Form 4: InspireMD COO Andrea Tommasoli Reports Stock and Options Transactions

Andrea Tommasoli, Chief Operating Officer of InspireMD, Inc., reports the acquisition and disposal of common stock and options.

Summary

• On January 7, 2025, Andrea Tommasoli, the Chief Operating Officer of InspireMD, Inc., engaged in transactions involving the company's common stock and options.
• Tommasoli acquired 232,616 shares of common stock at $0, increasing his holdings to 727,694 shares.
• These shares are restricted and vest in three equal annual installments starting January 7, 2026, contingent upon continued service.
• Tommasoli also acquired options to purchase 106,218 shares of common stock at an exercise price of $2.71, which also vest in three equal annual installments starting January 7, 2026, contingent upon continued service.
• Following the transaction, Tommasoli holds 282,917 options.
• A Power of Attorney was executed by Craig Shore on January 10, 2025, on behalf of Andrea Tommasoli.

Sentiment

Score: 5

Explanation: Neutral sentiment as it is a routine disclosure of insider transactions.

Positives

• The acquisition of shares and options by the COO could be interpreted as a sign of confidence in the company's future prospects.

Future Outlook

The vesting schedule of the restricted stock and options is contingent upon the Reporting Person's continued service.

Industry Context

This is a standard SEC Form 4 filing, reflecting changes in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.

Comparison to Industry Standards

• Insider transactions are a normal part of corporate governance.
• The vesting schedules are typical for executive compensation packages.
• Similar transactions are regularly reported by executives at comparable medical device companies.

Stakeholder Impact

• The transactions may provide stakeholders with insights into management's confidence in the company.

Key Dates